
Athira Pharma Inc (NASDAQ:ATHA) shares are falling Wednesday after the company announced topline results from its exploratory ACT-AD Phase 2 study of fosgonimeton in patients with mild-to-moderate Alzheimer's disease.
Athira said the primary endpoint of change in biomarker ERP P300 latency was not statistically significant in the study.